Iopromide

Iopromide
Clinical data
Trade namesUltravist
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • AU: B2
Routes of
administration		Intravascular
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding~1%
MetabolismNone
Elimination half-life2 hours
ExcretionKidneys
Identifiers
  • 1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-1-N-methylbenzene-1,3-dicarboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.070.330 Edit this at Wikidata
Chemical and physical data
FormulaC18H24I3N3O8
Molar mass791.116 g·mol−1
3D model (JSmol)
  • CN(CC(CO)O)C(=O)c1c(c(c(c(c1I)NC(=O)COC)I)C(=O)NCC(CO)O)I
  • InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29) ☒N
  • Key:DGAIEPBNLOQYER-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Iopromide is an iodinated contrast medium for X-ray imaging. It is marketed under the name Ultravist which is produced by Bayer Healthcare. It is a low osmolar, non-ionic contrast agent for intravascular use; i.e., it is injected into blood vessels.[2]

It is commonly used in radiographic studies such as intravenous urograms, brain computer tomography (CT)[2] and CT pulmonary angiograms (CTPAs).

Medical uses

The radiocontrast agent is given intravenously in computed tomography (CT) scans, angiography and excretory urography.[3]

Contraindications

Iopromide use is contraindicated in myelography, cerebral ventriculography and cisternography procedures. It is also contraindicated in those with hyperthyroidism, or with known allergy to the drug.[4]

Iopromide is also contraindicated in children with prolonged fasting, fluid restriction, on laxative, or dehydration as it can cause renal failure.[4]

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ a b Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Ultravist 300 mg J/ml-Infusionsflaschen.
  3. ^ "Prescribing information - Ultravist" (PDF). Bayer Healthcare pharmaceuticals. Archived from the original (PDF) on 10 April 2021.
  4. ^ a b "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ULTRAVIST® Iopromide Injection" (PDF). Bayer Healthcare Pharmaceuticals. Archived from the original (PDF) on 27 October 2021. Retrieved 16 April 2024.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.